Blockade Medical has announced the US Food and Drug Administration’s (FDA) 510(k) approval and the European CE Mark approval for the two additions to its Barricade coil system, which includes an enhanced framing coil and a new complex finishing coil.
The Barricade coil system is a comprehensive bare platinum coil line available in framing, filling and finishing shapes. The embolization coil line is designed to endovascularly occlude blood flow in vascular abnormalities of the neurovascular and peripheral vessels.
Blockade Medical president and chief technology officer Dave Ferrera noted the company is very proud of the clinically relevant enhancements to the Barricade coil line that it has delivered to the market in the past year including a handheld detachment cable set, longer coils and the recent approval of the enhanced framing and complex finishing coils.
"As we develop future coil and endoluminal technologies, we will continue to develop products that will make a positive clinical impact for clinicians and patients while also delivering compelling economic savings to the health care system," Ferrera added.
Blockade Medical obtained CE Mark approval in July 2012 and the FDA 510(k) approval in March 2013 for the Barricade coil system.